Research graph
References from Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for clinical trial design. Local targets link to admitted publications; unresolved targets remain external evidence.
Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
10.1158/2159-8290.cd-24-0027 · 2024 · External reference
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
10.1126/science.aec7929 · 2026 · External reference
Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer
10.1056/nejmoa2605555 · 2026 · External reference
Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134
10.1200/jco.22.01763 · 2023 · External reference
Altered gemcitabine and nab-paclitaxel scheduling improves therapeutic efficacy compared to standard concurrent treatment in pre-clinical models of pancreatic cancer
10.1158/1078-0432.ccr-20-1422 · 2021 · External reference
Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
10.1126/science.1171362 · 2009 · External reference
Endpoints for mouse abdominal tumor models: refinement of current criteria
2009 · External reference
Ras signals principally via Erk in G1 but cooperates with PI3K/Akt for Cyclin D induction and S-phase entry
10.1080/15384101.2018.1560205 · 2019 · External reference
